Included in the National Reimbursement Drug List (NRDL) and recognized as China's first generic equivalent.

Awarded the Third Prize of Chongqing Municipal Science and Technology Progress Award.

Honored with the China Patent Award.

Named the "Most Competitive Emerging Product of 2017".

Ranked No.1 in domestic market share for brand-name products.

The only domestic Hydrotalcite raw material to pass the FDA-DMF certification, meeting the highest international quality standards.

Chinese Consensus on Chronic Gastritis